Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694048 | 1.00 | FDPS (0.51) | FDPSCHRNA7CYP2A6NAPRTCYP1A2 | |
| SCHEMBL1696723 | 1.00 | FDPS (0.51) | FDPSCHRNA7CYP2A6NAPRTCYP1A2 | |
| SCHEMBL6754273 | 0.82 | KIF20A (0.48) | FDPSCHRNA7CYP2A6NAPRTCYP1A2 | |
| SCHEMBL2928425 | 0.82 | KIF20A (0.48) | FDPSCHRNA7CYP2A6NAPRTCYP1A2 | |
| SCHEMBL8171229 | 0.82 | FDPS (0.42) | FDPSCHRNA7CYP2A6NAPRTCYP1A2 | |
| SCHEMBL9770952 | 0.81 | FDPS (0.54) | FDPSCHRNA7CYP2A6NAPRTCYP1A2 | |
| SCHEMBL9852752 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2D6RECQLCYP3A4CYP2C9 | |
| SCHEMBL9395020 | 0.77 | LOXL2 (0.43) | CYP1A2CYP2D6CYP3A4CYP2C9HRH1 | |
| SCHEMBL1696676 | 0.77 | LOXL2 (0.43) | CYP1A2CYP2D6CYP3A4CYP2C9HRH1 | |
| SCHEMBL1696678 | 0.77 | LOXL2 (0.43) | CYP1A2CYP2D6CYP3A4CYP2C9HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| US-6191115-B1 | PEPTIDES AND POLYPEPTIDES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | claimed |
| WO-2000009544-A1 | HEPTAPEPTIDE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| US-5767082-A | ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1998-06-16 | — | — | US | claimed |
| US-4851385-A | LUTEINIZING HORMONE RELEASING HORMONE | INDIANA UNIVERSITY FOUNDATION (US) | 1989-07-25 | — | — | US | claimed |
| EP-0301850-A2 | LHRH antagonist analogs and 19-nor-progestational steroids for therapy | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0097031-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1988-09-21 | — | — | EP | claimed |
| EP-0277829-A2 | Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1988-08-10 | — | — | EP | claimed |
| US-4690916-A | ANTIFERTILITY AGENTS; HALO-SUBSTITUTED GUANADINO AMINO ACYL RESIDUE COMPONENT | SYNTEX (U.S.A.) INC. (US) | 1987-09-01 | — | — | US | claimed |
| EP-0111841-B1 | LHRH PREPARATIONS FOR INTRANASAL ADMINISTRATION | SYNTEX (U.S.A.) INC. (US) | 1987-05-06 | — | — | EP | claimed |
| EP-0182262-A2 | Nona and decapeptide analogs of LHRH useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1986-05-28 | — | — | EP | claimed |
| US-4481190-A | LUTEINIZING HORMONE RELEASING HORMONE | SYNTEX (U.S.A.) INC. (US) | 1984-11-06 | — | — | US | claimed |
| EP-0111841-A1 | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1984-06-27 | — | — | EP | claimed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | FDPS 4637/4885CHRNA7 22/4885CYP2A6 3402/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | FDPS 4637/4885CHRNA7 22/4885CYP2A6 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.